X0508 4 2024-09-20 false 0001710072 Edgewise Therapeutics, Inc. EWTX 0001644467 Carruthers R Michael C/O EDGEWISE THERAPEUTICS, INC. 1715 38TH STREET BOULDER CO 80301 false true false false Chief Financial Officer false Common Stock 2024-09-20 4 M false 46068.00 1.93 A 81996.00 D Common Stock 2024-09-20 4 S false 46068.00 28.5862 D 35928.00 D Common Stock 2024-09-20 4 S false 4064.00 28.5862 D 31864.00 D Common Stock 2024-09-20 4 S false 24960.00 28.5862 D 6904.00 D Common Stock 2024-09-20 4 M false 50000.00 1.93 A 56904.00 D Common Stock 2024-09-20 4 S false 50000.00 28.5477 D 6904.00 D Stock Option (Right to Buy) 1.93 2024-09-20 4 M false 96068.00 0.00 D 2030-12-15 Common Stock 96068.00 40990.00 D Includes 3,596 shares purchased on May 15, 2024 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan (the "ESPP"). 2,898 shares purchased on November 15, 2023 pursuant to the ESPP were properly reported on a Form 4 filed June 26, 2023 but erroneously added again to the balance reported on a Form 4 filed May 3, 2024. The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $27.80 to $28.79, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $28.81 to $29.06, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $28.26 to $28.95, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. 1/48th of the shares subject to the option vest each month beginning on January 3, 2021, subject to the Reporting Person continuing as a service provider through each vest date. /s/ John R. Moore Attorney-in-Fact for R. Michael Carruthers 2024-09-24